Request Demo
Last update 04 Apr 2026
Daratumumab biosimilar(Nanjing Shunxin Pharmaceutical)
Last update 04 Apr 2026
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms Daratumumab Biosimilar (Nanjing Shunxin Pharmaceutical Co., Ltd.), 达雷妥尤单抗生物类似药（Nanjing Shunxin Pharmaceutical Co., Ltd.）, TQB2709 |
Target |
Action inhibitors |
Mechanism CD38 inhibitors(Lymphocyte differentiation antigen CD38 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Antibody-dependent cellular phagocytosis (ADCP) effects |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 9075449L
The sequence is quoted from: *****
Sequence Code 9946743H
The sequence is quoted from: *****
Related
2
Clinical Trials associated with Daratumumab biosimilar(Nanjing Shunxin Pharmaceutical)CTR20241710
随机、双盲、单剂量、平行比较TQB2709注射液与兆珂®在健康男性志愿者中药代动力学和安全性相似性的I期临床研究
[Translation] A randomized, double-blind, single-dose, parallel phase I clinical study comparing the pharmacokinetics and safety of TQB2709 injection and Zhaoke® in healthy male volunteers
ChiCTR2400086256
A randomized, double-blind, single-dose, parallel-parallelized phase I clinical study comparing TQB2709 injection with Zhaoke ® in healthy male volunteers on pharmacokinetics and safety similarity
100 Clinical Results associated with Daratumumab biosimilar(Nanjing Shunxin Pharmaceutical)
Login to view more data
100 Translational Medicine associated with Daratumumab biosimilar(Nanjing Shunxin Pharmaceutical)
Login to view more data
100 Patents (Medical) associated with Daratumumab biosimilar(Nanjing Shunxin Pharmaceutical)
Login to view more data
100 Deals associated with Daratumumab biosimilar(Nanjing Shunxin Pharmaceutical)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Multiple Myeloma | Phase 1 | China | 15 Apr 2024 | |
| Relapse multiple myeloma | IND Approval | China | 28 Apr 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free